Targeting PI3K/AKT/mTOR network for treatment of leukemia.
about
Chondrocyte Apoptosis in the Pathogenesis of OsteoarthritisThe Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent CellsImmune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesBitterness in sugar: O-GlcNAcylation aggravates pre-B acute lymphocytic leukemia through glycolysis via the PI3K/Akt/c-Myc pathway.Monosodium Urate Crystal-Induced Chondrocyte Death via Autophagic Process.Hedyotis diffusa plus Scutellaria barbata Induce Bladder Cancer Cell Apoptosis by Inhibiting Akt Signaling Pathway through Downregulating miR-155 Expression.Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells.Butein inhibits cell proliferation and induces cell cycle arrest in acute lymphoblastic leukemia via FOXO3a/p27kip1 pathwayAssessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia.Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cellsThe tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signalingmiRNAs in acute myeloid leukemia.MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro.Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.In search for better pharmacological prophylaxis for acute mountain sickness: looking in other directions.The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.MicroRNAs as biomarkers in the diagnosis and treatment of chondrosarcoma.Significance of Inactivated Genes in Leukemia: Pathogenesis and PrognosisSTYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway.Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia.Icariside II promotes the osteogenic differentiation of canine bone marrow mesenchymal stem cells via the PI3K/AKT/mTOR/S6K1 signaling pathwaysAS1041, a Novel Synthesized Derivative of Marine Natural Compound Aspergiolide A, Arrests Cell Cycle, Induces Apoptosis, and Inhibits ERK Activation in K562 Cells.ERp29 inhibits tumorigenicity by suppressing epithelial mesenchymal transition in gastric cancer.Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.How is the relationship between TWIST-1 and BCR-ABL1 gene expressions in Chronic Myeloid Leukemia Patients?Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients.Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo.Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia.A novel reporter for real-time, quantitative imaging of AKT-directed K63-poly-ubiquitination in living cells.Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathwayBiological Aspects of mTOR in Leukemia
P2860
Q26777068-FFE484C5-4BA5-45A5-80DA-A1BD005B671EQ28074203-E7EC4AAC-BB0F-4C83-9EAE-BA16518BE548Q28081001-E5EF1250-BC82-4F3F-B737-768363812C4BQ33850060-5A555EFA-59B1-4568-AC4E-CE92EAE6766DQ36404177-B5B6A10A-66F8-4F0E-96FE-96486B029904Q36637505-95A3198F-7049-42A2-BA19-B92FDA902AB3Q37021907-4973F37B-6596-4086-A9C1-2D8DC4DB29A9Q37109845-E81E8A21-AE0D-420C-9BEB-CDC214D7E96AQ37362785-DC5804D9-4A13-4F6B-BA13-EC961F430FEAQ37409768-2054D1E0-1DF2-49AF-88B0-2DD4F64D103EQ37709259-B320A311-6CCB-45C2-A6C9-45705CCB8020Q37709531-CA67697B-47DD-4D4F-A189-75D94ABCA485Q37714078-B1B34F10-F93A-473D-A940-901595F3B10CQ37720022-6FB023E3-84F6-4D78-AB9E-A01A21D33E11Q38380577-E6BA1EBC-6945-47AF-99A5-D90E640E66E6Q38729618-1B564CD7-2D3B-44D7-88BE-E8090C40643EQ38778888-AB713F0E-3EF5-4B60-B9FC-B089D4D25F87Q38812518-C4631816-5BB0-4D18-8D30-350BE6A85A4BQ39350173-DEF77FD8-2461-401B-975D-347D108A08C9Q41097923-24CA9DAF-135B-4CD6-9CC1-B3F7C41CB163Q41623491-60986690-C591-4D7B-8568-4C6ED11A0514Q42026999-2E325860-0439-4297-B3F6-EB04DA97DBACQ42068004-D72ABFBF-CBC2-484E-8E48-7C5C365A89C6Q42242030-64FBBFA4-91EF-4C82-A34D-3E38BA25A2BAQ47099298-3937619F-2835-47C3-8B48-4697BA450ED5Q47136458-DF9F44D3-8E3E-4A2E-BBFF-08CC7F638DD3Q47233124-394406CF-40FD-4578-A942-98AFEDEF3DF8Q47235766-0EEE82B3-0206-4B00-8CD2-0FC227FD5EFBQ48057652-377F9D0B-F467-4A6D-9DFC-C631F7940D0DQ48534841-22109B45-DA07-4DFD-98BB-B0306CD010ADQ50129481-224C44B0-0B8C-43E4-B32A-BD615932EBE0Q54261746-6F92A812-BBAD-4D3F-9981-4EAA0F2E9B7AQ54974008-D7F2EA95-5375-4DA0-8003-98BCF5CE709AQ58754071-96108996-483B-4ABF-89E4-81337EFA8618Q58780065-68ADA02E-82BA-4951-9B57-09CA1E931F71
P2860
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
@en
type
label
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
@en
prefLabel
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
@en
P2860
P50
P1476
Targeting PI3K/AKT/mTOR network for treatment of leukemia
@en
P2093
Mohammad Shahjahani
P2860
P2888
P304
P356
10.1007/S00018-015-1867-5
P577
2015-02-25T00:00:00Z